Economic Analysis of  Inadequate Symptom Control in Carcinoid Cyndrome in the United States

Burton, Tanya; Lapuerta, Pablo

doi:10.2217/fon-2018-0129

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the 1980s, somatostatin analog (SSA) therapy has been the first‐line medical management approach for CS symptoms and CSD . Approximately 60% of patients may be responsive to initial SSA long‐acting release (LAR) treatment, but they have shown a loss of effect over time, resulting in refractory symptoms . Other treatment options with the potential to palliate CS or delay its progression include hepatic arterial embolization and peptide receptor radiotherapy, which are generally recommended for patients with radiographic progression rather than those with symptom progression in the setting of stable disease .…”

Section: Introductionmentioning

confidence: 99%

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Adjusted annual costs were also higher among those with CSD (CSD, $81610 vs CS only, $51719), but lower than those observed in this study (CSD, $105153 vs CS only, $54701). Burton and Lapuerta analyzed medical claims for US adults with CS and inadequate symptom control from somatostatin analog therapy[16]. The proportion of patients with CSD-related ED visits and hospitalizations nearly doubled (9% to 16%) following escalation of somatostatin analog therapy doses, considered a proxy for CS symptom severity, which incurred higher all-cause healthcare costs ($8305 vs $4116 per patient per month).…”

Section: Discussionmentioning

confidence: 99%

Direct costs of carcinoid syndrome diarrhea among adults in the United States

Dasari¹,

Joish²,

Perez-Olle³

et al. 2019

WJG

View full text Add to dashboard Cite

BACKGROUNDThe burden of carcinoid syndrome (CS) among patients with neuroendocrine tumors is substantial and has been shown to result in increased healthcare resource use and costs. The incremental burden of CS diarrhea (CSD) is less well understood, particularly among working age adults who make up a large proportion of the population of patients with CS.AIMTo estimate the direct medical costs of CSD to a self-insured employer in the United States.METHODSCS patients with and without CSD were identified in the IBM® MarketScan® Database, including the Medicare Supplemental Coordination of Benefits database. Eligible patients had ≥ 1 medical claim for CS with continuous health plan enrollment for ≥ 12 mo prior to their first CS diagnosis and for ≥ 30 d after, no claims for acromegaly, and no clinical trial participation during the study period (2014-2016). Baseline demographic and clinical characteristics, including comorbidities and treatment, were analyzed using descriptive statistics. Measures of healthcare resource use and costs were compared between patients with and without CSD, including Emergency Department (ED) visits, hospital admissions and length of stay, physician office visits, outpatient services, and prescription claims, using univariate and multivariate analyses to evaluate associations of CSD with healthcare resource use and costs, controlling for baseline characteristics.RESULTSOverall, 6855 patients with CS were identified of which 4,043 were eligible for the analysis (1352 with CSD, 2691 with CS only). Baseline demographic and clinical characteristics were similar between groups with the exception of age, underlying tumor type, and health insurance plan. Patients with CSD were older, had more comorbidities, and received more somatostatin analog therapy at baseline. Patients with CSD required greater use of healthcare resources and incurred higher costs than their peers without CSD, including hospitalizations (44% vs 25%) and ED visits (55% vs 31%). The total adjusted annual healthcare costs per patient were 50% higher (+ $23865) among those with CSD, driven by outpatient services (+ 56%), prescriptions (+ 48%), ED visits (+ 26%), physician office visits (+ 21%), and hospital admissions (+ 11%).CONCLUSIONThe economic burden of CSD is greater than that of CS alone among insured working age adults in the United States, which may benefit from timely diagnosis and management.

show abstract

A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome

et al. 2021

View full text Add to dashboard Cite

Economic Analysis of Inadequate Symptom Control in Carcinoid Cyndrome in the United States

Abstract: Higher mean pre-escalation per-patient per-month resource use and costs post-escalation primarily attributable to CS-related ambulatory care suggests continuing challenges in managing CS despite octreotide dose escalation.

Cited by 6 publications

References 30 publications

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

Direct costs of carcinoid syndrome diarrhea among adults in the United States

A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome

Contact Info

Product

Resources

About